Bayer Aktiengesellschaft (ETR:BAYN)

Germany flag Germany · Delayed Price · Currency is EUR
38.88
-0.65 (-1.66%)
At close: Jan 9, 2026
97.70%
Market Cap38.20B
Revenue (ttm)45.87B
Net Income (ttm)-198.00M
Shares Out982.42M
EPS (ttm)-0.20
PE Ration/a
Forward PE9.72
Dividend0.11 (0.28%)
Ex-Dividend DateApr 28, 2025
Volume3,533,159
Average Volume3,508,986
Open39.23
Previous Close39.54
Day's Range38.69 - 39.35
52-Week Range18.38 - 40.00
Beta0.89
RSI72.17
Earnings DateFeb 25, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 91,864
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BAYN
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial Statements

News

Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.

1 day ago - Nasdaq

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

Bayer and Soufflé Therapeutics, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to ...

2 days ago - Wallstreet:Online

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration...

2 days ago - Business Wire

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

Cradle provides a scientific AI software platform focused on protein engineering Bayer continues to utilize AI in R&D, reinforcing commitment to modernize and scale its drug discovery and development ...

3 days ago - Benzinga

Bayer sues COVID vaccine makers over mRNA technology

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...

3 days ago - Reuters

Pesticide industry ‘immunity shield’ stripped from US appropriations bill

Democrats and the Make America Healthy Again movement pushed back on the rider in a funding bill led by Bayer In a setback for the pesticide industry, Democrats have succeeded in removing a rider from...

4 days ago - The Guardian

Bayer-Krebsmittel Sevabertinib in USA und China mit Breakthrough-Therapy-Status

DJ Bayer-Krebsmittel Sevabertinib in USA und China mit Breakthrough-Therapy-Status DOW JONES--Bayer hat für sein Krebsmedikament Sevabertinib von den Zulassungsbehörden in den USA und China den St...

4 days ago - Finanz Nachrichten

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan's 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board o...

5 days ago - Business Wire

BAYRY's 2025 Revival: Will the Momentum Continue in 2026?

BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.

10 days ago - Nasdaq

DCM Shriram shares rally sharply 6% as company signs strategic MoU with Bayer to boost agri-innovation

DCM Shriram shares surged more than 6% after the company announced a strategic Memorandum of Understanding (MoU) with Bayer Crop...

4 weeks ago - Business Upturn

DCM Shriram and Bayer Crop Science sign strategic MoU to advance sustainable agriculture in India

DCM Shriram Limited and Bayer Crop Science Limited have entered into a strategic Memorandum of Understanding (MoU) aimed at advancing...

4 weeks ago - Business Upturn

EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis

EQS-News: IBM / Key word(s): Product Launch Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis 05.12.2025 / 09:05 CET/CEST The issuer is solely responsible for the co...

5 weeks ago - Wallstreet:Online

Tandem Global e.V. Announces New Supervisory Board Members From AECOM, Bayer, and CRH

Trio joins Dow's Dr. Jihane Ball to provide critical guidance to the organisation's European initiatives MUNICH, DE / ACCESS Newswire / December 4, 2025 / Tandem Global, e.V., the European entity o...

5 weeks ago - Finanz Nachrichten

EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...

5 weeks ago - Wallstreet:Online

Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment

Bayer and Evotec are advancing a new hope for Alport syndrome, testing a targeted antibody in a rigorous Phase 2 trial to improve outcomes for young adults.

5 weeks ago - Wallstreet:Online

EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome 04.12.2025 / 08:30 CET/CEST The issuer is solely responsible f...

5 weeks ago - Wallstreet:Online

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A ...

5 weeks ago - Business Wire

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-base...

5 weeks ago - Wallstreet:Online

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigati...

5 weeks ago - Business Wire

Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study

Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study

5 weeks ago - GuruFocus

Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit

Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit

5 weeks ago - GuruFocus

Bayer Welcomes Solicitor General Support In Supreme Court Review Of Roundup Case

(RTTNews) - Bayer (BAYN.DE) Tuesday said it is "pleased" by the U.S. Solicitor General's support for Supreme Court review of its petition in the Durnell case, calling the government's backing a signif...

5 weeks ago - Nasdaq

Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today

Shares of Bayer are surging on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review rulings on whether Roundup weed killer, produced b...

5 weeks ago - Investopedia